Sharps Technology (STSS) said Wednesday it has initiated first shipments of its SecureGard and SoloGard smart safety syringes relating to three client orders from its manufacturing site in Hungary.
The company began shipment of its first commercial order of Sologard to a US-based IV flushing services provider under a previously announced $50 million agreement, while it has also delivered SecureGard syringes to a Hungarian vaccine provider after securing a $100,000 purchase order, Sharps said.
The total purchase commitments reached roughly $500,000 with the two orders, the company said.
The medical device and pharmaceutical packaging company also said it started a 200,000-unit shipment of 1mL low dead-volume syringes to a Switzerland-based global provider of cosmetic, dental, and ophthalmic injectable therapies.
Shares were up more than 53% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。